JP2004534065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534065A5 JP2004534065A5 JP2003503625A JP2003503625A JP2004534065A5 JP 2004534065 A5 JP2004534065 A5 JP 2004534065A5 JP 2003503625 A JP2003503625 A JP 2003503625A JP 2003503625 A JP2003503625 A JP 2003503625A JP 2004534065 A5 JP2004534065 A5 JP 2004534065A5
- Authority
- JP
- Japan
- Prior art keywords
- azabicyclo
- oct
- carboxamide
- methyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 phenoxy, substituted phenoxy Chemical group 0.000 claims 84
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 50
- 125000000753 cycloalkyl group Chemical group 0.000 claims 42
- 125000001424 substituent group Chemical group 0.000 claims 35
- 229910052794 bromium Inorganic materials 0.000 claims 34
- 229910052801 chlorine Inorganic materials 0.000 claims 34
- 229910052731 fluorine Inorganic materials 0.000 claims 33
- 125000000547 substituted alkyl group Chemical group 0.000 claims 32
- 229910052717 sulfur Inorganic materials 0.000 claims 28
- 229910052740 iodine Inorganic materials 0.000 claims 27
- 229910052760 oxygen Inorganic materials 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 229910052757 nitrogen Inorganic materials 0.000 claims 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims 22
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 17
- 125000001624 naphthyl group Chemical group 0.000 claims 16
- 150000001350 alkyl halides Chemical class 0.000 claims 15
- 241000124008 Mammalia Species 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 10
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 230000037396 body weight Effects 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 4
- 239000000164 antipsychotic agent Substances 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 4
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 4
- ZZXJOYOEQRWJDL-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(C=NN2)C2=C1 ZZXJOYOEQRWJDL-BONVTDFDSA-N 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- GBUOQYCQICLFNH-ZBEGNZNMSA-N 2,2-dimethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(OC(C)(C)O2)C2=C1 GBUOQYCQICLFNH-ZBEGNZNMSA-N 0.000 claims 2
- UQIBUSORBPFLMW-GTNSWQLSSA-N 2-cyclopropyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-5-carboxamide Chemical compound N([C@H]1[C@@H](N2CCC1CC2)C)C(=O)C(C=C1N=2)=CC=C1OC=2C1CC1 UQIBUSORBPFLMW-GTNSWQLSSA-N 0.000 claims 2
- QBHISQDVYPZIER-GTNSWQLSSA-N 2-cyclopropyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-6-carboxamide Chemical compound N([C@H]1[C@@H](N2CCC1CC2)C)C(=O)C(C=C1O2)=CC=C1N=C2C1CC1 QBHISQDVYPZIER-GTNSWQLSSA-N 0.000 claims 2
- CKGNGQUUKYSLRO-HVPTUWJBSA-N 2-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C2OC(CC)OC2=C1 CKGNGQUUKYSLRO-HVPTUWJBSA-N 0.000 claims 2
- NZLVGHVPGBVCLV-GTNSWQLSSA-N 2-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C(SC(CC)=N2)C2=C1 NZLVGHVPGBVCLV-GTNSWQLSSA-N 0.000 claims 2
- WLJJFLHJQCUFOI-GTNSWQLSSA-N 2-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-6-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C2N=C(CC)SC2=C1 WLJJFLHJQCUFOI-GTNSWQLSSA-N 0.000 claims 2
- FDHBLNSFHYLDEH-HOVBKMTKSA-N 2-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C2OC(C)OC2=C1 FDHBLNSFHYLDEH-HOVBKMTKSA-N 0.000 claims 2
- ZJXLESZRGMQWPN-QFYYESIMSA-N 2-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(OC(C)=N2)C2=C1 ZJXLESZRGMQWPN-QFYYESIMSA-N 0.000 claims 2
- VALPOKIADDYPRS-GTNSWQLSSA-N 3-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C2SN=C(CC)C2=C1 VALPOKIADDYPRS-GTNSWQLSSA-N 0.000 claims 2
- ZLSUBDFSPCIPQE-GTNSWQLSSA-N 3-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2h-indazole-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C2NN=C(CC)C2=C1 ZLSUBDFSPCIPQE-GTNSWQLSSA-N 0.000 claims 2
- UJQZUOZUIBOLSN-GTNSWQLSSA-N 3-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2h-indazole-6-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C2C(CC)=NNC2=C1 UJQZUOZUIBOLSN-GTNSWQLSSA-N 0.000 claims 2
- NHGGNDKSIJWLTD-ZBEGNZNMSA-N 3-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(SN=C2C)C2=C1 NHGGNDKSIJWLTD-ZBEGNZNMSA-N 0.000 claims 2
- HXZRWLSVDMDTLO-ZBEGNZNMSA-N 3-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzoxazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(C(C)=NO2)C2=C1 HXZRWLSVDMDTLO-ZBEGNZNMSA-N 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 206010036631 Presenile dementia Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 2
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 230000006399 behavior Effects 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 208000030963 borderline personality disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 231100000870 cognitive problem Toxicity 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- XXYLBRKFHOKBKJ-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(SN=C2)C2=C1 XXYLBRKFHOKBKJ-BONVTDFDSA-N 0.000 claims 2
- FYGIRVSZYNMHQG-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(N=CS2)C2=C1 FYGIRVSZYNMHQG-BONVTDFDSA-N 0.000 claims 2
- NBEWJBQXYRFMLA-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(N=CO2)C2=C1 NBEWJBQXYRFMLA-BONVTDFDSA-N 0.000 claims 2
- LQMVYBGIFKNQDC-CABZTGNLSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1h-imidazo[4,5-b]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=NC2=CC=CN=C2N1 LQMVYBGIFKNQDC-CABZTGNLSA-N 0.000 claims 2
- ZKHBKNUQLYMXDG-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(NN=C2)C2=C1 ZKHBKNUQLYMXDG-BONVTDFDSA-N 0.000 claims 2
- CQMGHERKYXDKGS-SJCJKPOMSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(CCC2)C2=C1 CQMGHERKYXDKGS-SJCJKPOMSA-N 0.000 claims 2
- BCAXPXRFVVJHEH-ZBEGNZNMSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-benzofuran-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=COC=C2C=C1 BCAXPXRFVVJHEH-ZBEGNZNMSA-N 0.000 claims 2
- VWACRKAORSYBGM-XPTSAGLGSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]dioxolo[4,5-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OCO2 VWACRKAORSYBGM-XPTSAGLGSA-N 0.000 claims 2
- ACYMIDOZHLIIDH-XPTSAGLGSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]oxazolo[5,4-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=N2 ACYMIDOZHLIIDH-XPTSAGLGSA-N 0.000 claims 2
- IGGXAPWVSWLNEQ-XPTSAGLGSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]thiazolo[5,4-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=N2 IGGXAPWVSWLNEQ-XPTSAGLGSA-N 0.000 claims 2
- YUVZMBZYGRCOFJ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-5-carboxamide Chemical compound C1=C2SN=CC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 YUVZMBZYGRCOFJ-ZDUSSCGKSA-N 0.000 claims 2
- NMVQZDSWLUQTNK-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-2-carboxamide Chemical compound C1=CC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=NC2=C1 NMVQZDSWLUQTNK-LBPRGKRZSA-N 0.000 claims 2
- ZLYNXTYFPVYJKB-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-6-carboxamide Chemical compound C1=C2N=CSC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 ZLYNXTYFPVYJKB-ZDUSSCGKSA-N 0.000 claims 2
- FDHHAJRIMDJGMH-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-5-carboxamide Chemical compound C1=C2OC=NC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 FDHHAJRIMDJGMH-ZDUSSCGKSA-N 0.000 claims 2
- NAVFMODLBCXAFU-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-6-carboxamide Chemical compound C1=C2N=COC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 NAVFMODLBCXAFU-ZDUSSCGKSA-N 0.000 claims 2
- XCKJZOIVIGYSLU-NSHDSACASA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1h-imidazo[4,5-b]pyridine-2-carboxamide Chemical compound C1=CN=C2NC(C(N[C@@H]3C4CCN(CC4)C3)=O)=NC2=C1 XCKJZOIVIGYSLU-NSHDSACASA-N 0.000 claims 2
- FMPRLHKUGFEBGZ-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-5-carboxamide Chemical compound C1=C2NN=CC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 FMPRLHKUGFEBGZ-AWEZNQCLSA-N 0.000 claims 2
- OYCAIFKXULCOPU-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-6-carboxamide Chemical compound C1=C2C=NNC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 OYCAIFKXULCOPU-AWEZNQCLSA-N 0.000 claims 2
- ACDZFDXMIHVLBR-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-benzofuran-5-carboxamide Chemical compound C1=CC2=COC=C2C=C1C(=O)N[C@@H]1C(CC2)CCN2C1 ACDZFDXMIHVLBR-HNNXBMFYSA-N 0.000 claims 2
- FKGDRPLPZMMVPC-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyclopropyl-1,3-benzothiazole-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=C1N=2)=CC=C1SC=2C1CC1 FKGDRPLPZMMVPC-HNNXBMFYSA-N 0.000 claims 2
- XYYQAWWDSVMDQT-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyclopropyl-1,3-benzothiazole-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=C1S2)=CC=C1N=C2C1CC1 XYYQAWWDSVMDQT-HNNXBMFYSA-N 0.000 claims 2
- JSMKHSWTUIRJLL-KNVGNIICSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethyl-1,3-benzodioxole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2OC(CC)OC2=C1 JSMKHSWTUIRJLL-KNVGNIICSA-N 0.000 claims 2
- HLFZWDHHGNPLSW-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethyl-1,3-benzothiazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2N=C(CC)SC2=C1 HLFZWDHHGNPLSW-AWEZNQCLSA-N 0.000 claims 2
- VJZFNODTMSQKHX-HQVZTVAUSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-1,3-benzodioxole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2OC(C)OC2=C1 VJZFNODTMSQKHX-HQVZTVAUSA-N 0.000 claims 2
- AVLPFTONOYMLAG-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-1,3-benzothiazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2N=C(C)SC2=C1 AVLPFTONOYMLAG-AWEZNQCLSA-N 0.000 claims 2
- GTDDJGZNXMIDBO-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C(OC(C)=N2)C2=C1 GTDDJGZNXMIDBO-AWEZNQCLSA-N 0.000 claims 2
- WDNUBGGUCNFQNH-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-1,3-benzoxazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2N=C(C)OC2=C1 WDNUBGGUCNFQNH-AWEZNQCLSA-N 0.000 claims 2
- YPRAGUDVXLJXAB-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethyl-1,2-benzothiazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2C(CC)=NSC2=C1 YPRAGUDVXLJXAB-HNNXBMFYSA-N 0.000 claims 2
- WXRPTNANGLOIRN-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethyl-2h-indazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2NN=C(CC)C2=C1 WXRPTNANGLOIRN-INIZCTEOSA-N 0.000 claims 2
- HBDREIXEFJYNGV-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethyl-2h-indazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2C(CC)=NNC2=C1 HBDREIXEFJYNGV-INIZCTEOSA-N 0.000 claims 2
- GTWYZSZFHSSCBE-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methyl-1,2-benzothiazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2SN=C(C)C2=C1 GTWYZSZFHSSCBE-AWEZNQCLSA-N 0.000 claims 2
- CGNCXTRJLPTFKG-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methyl-1,2-benzothiazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2C(C)=NSC2=C1 CGNCXTRJLPTFKG-AWEZNQCLSA-N 0.000 claims 2
- KRUJHSPNZBAMJO-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methyl-1,2-benzoxazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2ON=C(C)C2=C1 KRUJHSPNZBAMJO-AWEZNQCLSA-N 0.000 claims 2
- MZDICAFUBOEFAC-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methyl-1,2-benzoxazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2C(C)=NOC2=C1 MZDICAFUBOEFAC-AWEZNQCLSA-N 0.000 claims 2
- VEXZGFQSRCEGGU-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methyl-2h-indazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2NN=C(C)C2=C1 VEXZGFQSRCEGGU-HNNXBMFYSA-N 0.000 claims 2
- XQSAWZAMTNEKFZ-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methyl-2h-indazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2C(C)=NNC2=C1 XQSAWZAMTNEKFZ-HNNXBMFYSA-N 0.000 claims 2
- DJVMAUCAWGPQON-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3h-imidazo[4,5-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1N=CN2 DJVMAUCAWGPQON-ZDUSSCGKSA-N 0.000 claims 2
- AVNWRJIONXJXCT-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-fluoro-1,3-benzothiazole-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC2=CC=C(F)C=C2S1 AVNWRJIONXJXCT-LBPRGKRZSA-N 0.000 claims 2
- IYKQEGPAWNKXQE-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]oxazolo[5,4-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=N2 IYKQEGPAWNKXQE-LBPRGKRZSA-N 0.000 claims 2
- YOCAVDNIDQJJHQ-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzodioxole-5-carboxamide Chemical compound C1=C2OCOC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 YOCAVDNIDQJJHQ-GFCCVEGCSA-N 0.000 claims 2
- NMVQZDSWLUQTNK-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-2-carboxamide Chemical compound C1=CC=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=NC2=C1 NMVQZDSWLUQTNK-GFCCVEGCSA-N 0.000 claims 2
- ZLYNXTYFPVYJKB-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-6-carboxamide Chemical compound C1=C2N=CSC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 ZLYNXTYFPVYJKB-CYBMUJFWSA-N 0.000 claims 2
- NAVFMODLBCXAFU-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-6-carboxamide Chemical compound C1=C2N=COC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 NAVFMODLBCXAFU-CYBMUJFWSA-N 0.000 claims 2
- OYCAIFKXULCOPU-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-6-carboxamide Chemical compound C1=C2C=NNC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 OYCAIFKXULCOPU-CQSZACIVSA-N 0.000 claims 2
- GTDDJGZNXMIDBO-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-1,3-benzoxazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=CC=C(OC(C)=N2)C2=C1 GTDDJGZNXMIDBO-CQSZACIVSA-N 0.000 claims 2
- MZDICAFUBOEFAC-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-methyl-1,2-benzoxazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=CC=C2C(C)=NOC2=C1 MZDICAFUBOEFAC-CQSZACIVSA-N 0.000 claims 2
- IYKQEGPAWNKXQE-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]oxazolo[5,4-c]pyridine-6-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=N2 IYKQEGPAWNKXQE-GFCCVEGCSA-N 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- MKBDWFXMHKBBGT-UHFFFAOYSA-N 1,2-benzoxazole-5-carboxamide Chemical compound NC(=O)C1=CC=C2ON=CC2=C1 MKBDWFXMHKBBGT-UHFFFAOYSA-N 0.000 claims 1
- CUONPNOUJUNHNL-GTNSWQLSSA-N 2-cyclopropyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-6-carboxamide Chemical compound N([C@H]1[C@@H](N2CCC1CC2)C)C(=O)C(C=C1S2)=CC=C1N=C2C1CC1 CUONPNOUJUNHNL-GTNSWQLSSA-N 0.000 claims 1
- OIVUSUAXZQDKGO-QFYYESIMSA-N 2-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(SC(C)=N2)C2=C1 OIVUSUAXZQDKGO-QFYYESIMSA-N 0.000 claims 1
- GTVLLBYFLCNDIN-QFYYESIMSA-N 2-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(N=C(C)S2)C2=C1 GTVLLBYFLCNDIN-QFYYESIMSA-N 0.000 claims 1
- PUNUVCDDNQSOOA-QFYYESIMSA-N 2-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(N=C(C)O2)C2=C1 PUNUVCDDNQSOOA-QFYYESIMSA-N 0.000 claims 1
- BZCVBJVGPQRBJC-GTNSWQLSSA-N 3-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-6-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=CC=C2C(CC)=NSC2=C1 BZCVBJVGPQRBJC-GTNSWQLSSA-N 0.000 claims 1
- HSMFTLXHYNRLPJ-ZBEGNZNMSA-N 3-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(C(C)=NS2)C2=C1 HSMFTLXHYNRLPJ-ZBEGNZNMSA-N 0.000 claims 1
- HPPQHNRAKBLSRH-ZBEGNZNMSA-N 3-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2h-indazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(NN=C2C)C2=C1 HPPQHNRAKBLSRH-ZBEGNZNMSA-N 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- PPFWJHGTTCSSQG-UHFFFAOYSA-N [1,3]oxazolo[4,5-c]pyridine-6-carboxamide Chemical compound O1C=NC=2C=NC(=CC=21)C(=O)N PPFWJHGTTCSSQG-UHFFFAOYSA-N 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- BIABVKWOSOQZMP-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(C=NS2)C2=C1 BIABVKWOSOQZMP-BONVTDFDSA-N 0.000 claims 1
- DWBMACOTCBKKPO-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzothiazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(SC=N2)C2=C1 DWBMACOTCBKKPO-BONVTDFDSA-N 0.000 claims 1
- IJAGJYXMEUXBCO-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1,3-benzoxazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(OC=N2)C2=C1 IJAGJYXMEUXBCO-BONVTDFDSA-N 0.000 claims 1
- XXRIDUSOQDPDON-ZBEGNZNMSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2h-isoindole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CNC=C2C=C1 XXRIDUSOQDPDON-ZBEGNZNMSA-N 0.000 claims 1
- YSSJYTORFPIHDF-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3h-benzimidazole-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(NC=N2)C2=C1 YSSJYTORFPIHDF-BONVTDFDSA-N 0.000 claims 1
- MRKNECRSVRDYAK-XPTSAGLGSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]oxazolo[4,5-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1N=CO2 MRKNECRSVRDYAK-XPTSAGLGSA-N 0.000 claims 1
- UXMIUDXPNBLUHE-XPTSAGLGSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]thiazolo[4,5-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1N=CS2 UXMIUDXPNBLUHE-XPTSAGLGSA-N 0.000 claims 1
- LMLCKGNCJTUPAG-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyclopropyl-1,3-benzoxazole-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=C1N=2)=CC=C1OC=2C1CC1 LMLCKGNCJTUPAG-HNNXBMFYSA-N 0.000 claims 1
- VXEVJNCMQZFTBG-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethyl-1,3-benzothiazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C(SC(CC)=N2)C2=C1 VXEVJNCMQZFTBG-AWEZNQCLSA-N 0.000 claims 1
- QRQVGKXXEOQYDA-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2h-isoindole-5-carboxamide Chemical compound C1=CC2=CNC=C2C=C1C(=O)N[C@@H]1C(CC2)CCN2C1 QRQVGKXXEOQYDA-HNNXBMFYSA-N 0.000 claims 1
- YGZCNTIFLAJTDF-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethyl-1,2-benzothiazole-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC=C2SN=C(CC)C2=C1 YGZCNTIFLAJTDF-HNNXBMFYSA-N 0.000 claims 1
- KZDQJAQBRPWVOF-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3h-benzimidazole-5-carboxamide Chemical compound C1=C2NC=NC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 KZDQJAQBRPWVOF-AWEZNQCLSA-N 0.000 claims 1
- CRJANQYWKDYOQV-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]oxazolo[4,5-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1N=CO2 CRJANQYWKDYOQV-LBPRGKRZSA-N 0.000 claims 1
- XCIXZKZDZTUSKD-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1,3]thiazolo[4,5-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1N=CS2 XCIXZKZDZTUSKD-LBPRGKRZSA-N 0.000 claims 1
- XCKJZOIVIGYSLU-LLVKDONJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-imidazo[4,5-b]pyridine-2-carboxamide Chemical compound C1=CN=C2NC(C(N[C@H]3C4CCN(CC4)C3)=O)=NC2=C1 XCKJZOIVIGYSLU-LLVKDONJSA-N 0.000 claims 1
- WDNUBGGUCNFQNH-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-1,3-benzoxazole-6-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=CC=C2N=C(C)OC2=C1 WDNUBGGUCNFQNH-CQSZACIVSA-N 0.000 claims 1
- AVNWRJIONXJXCT-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-fluoro-1,3-benzothiazole-2-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC2=CC=C(F)C=C2S1 AVNWRJIONXJXCT-GFCCVEGCSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29763301P | 2001-06-12 | 2001-06-12 | |
| US29763101P | 2001-06-12 | 2001-06-12 | |
| US29763001P | 2001-06-12 | 2001-06-12 | |
| US29762901P | 2001-06-12 | 2001-06-12 | |
| US29763201P | 2001-06-12 | 2001-06-12 | |
| US32854801P | 2001-10-11 | 2001-10-11 | |
| US37349602P | 2002-04-18 | 2002-04-18 | |
| PCT/US2002/016570 WO2002100858A2 (en) | 2001-06-12 | 2002-06-06 | Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004534065A JP2004534065A (ja) | 2004-11-11 |
| JP2004534065A5 true JP2004534065A5 (OSRAM) | 2005-12-22 |
Family
ID=27569622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003503625A Withdrawn JP2004534065A (ja) | 2001-06-12 | 2002-06-06 | 疾患治療用のキヌクリジン置換二環系へテロ芳香族化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6828330B2 (OSRAM) |
| EP (1) | EP1404674A2 (OSRAM) |
| JP (1) | JP2004534065A (OSRAM) |
| AR (1) | AR036041A1 (OSRAM) |
| AU (1) | AU2002348503A1 (OSRAM) |
| CA (1) | CA2445471A1 (OSRAM) |
| PE (1) | PE20030040A1 (OSRAM) |
| WO (1) | WO2002100858A2 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| SK288115B6 (sk) * | 2002-09-25 | 2013-09-03 | Memory Pharmaceuticals Corporation | Indazoles, pharmaceutical compositions comprising them and their use |
| MXPA05004723A (es) * | 2002-11-01 | 2005-12-05 | Pharmacia & Upjohn Co Llc | Compuestos que tienen ambas actividades del agonista alfa 7 nachr y el antagonista 5ht para el tratamiento de las enfermedades del snc. |
| AU2003269413A1 (en) * | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| EP1587511A2 (en) * | 2003-01-22 | 2005-10-26 | Pharmacia & Upjohn Company LLC | Treatment of diseases with alpha-7 nach receptor full agonists |
| WO2004099202A1 (en) * | 2003-05-05 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases |
| GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| JP4824578B2 (ja) | 2003-12-22 | 2011-11-30 | メモリー・ファーマシューティカルズ・コーポレイション | インドール類、１，２−ベンズイソオキサゾール類、および１，２−ベンゾイソチアゾール類、ならびにそれらの製造と使用 |
| MXPA06010852A (es) | 2004-03-25 | 2007-01-16 | Memory Pharm Corp | Indazoles, benzotiazoles, benzoisotiazoles, bencisoxazoles y preparacion y usos de los mismos. |
| WO2006001894A1 (en) * | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| KR20070015607A (ko) * | 2004-05-07 | 2007-02-05 | 메모리 파마슈티칼스 코포레이션 | 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도 |
| CA2591817A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| WO2006089100A1 (en) * | 2005-02-17 | 2006-08-24 | Amr Technology, Inc. | Benzoxazole carboxamides for treating cinv and ibs-d |
| BRPI0617534A2 (pt) * | 2005-09-23 | 2011-07-26 | Memory Pharm Corp | Composto, composição farmacêutica, método para a ativação/estimulação seletiva de receptores nicotínicos de a-7 em um paciente, método para o tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de degeneração da memória e/ou da cognição, método para o tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método para o tratamento de um paciente que sofre de degeneração da memória devida à degeneração cognitiva suave devida ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do cns, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método para o tratamento e/ou a prevenção da demência em um paciente com mal de alzheimer, método para o tratamento de um paciente para a retirada do álcool ou para o tratamento de um paciente com terapia anti-intoxicação, método para o tratamento de um paciente para conferir neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamato, método para o tratamento de um paciente que sofre de vício de nicotina, dor, tontura de fuso horário, obesidade e/ou diabetes, método de indução de um paciente a parar de fumar, método para o tratamento de um paciente que sofre de degeneração cognitiva suave (mci), demência vascular (vad), declínio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia de coração aberto, apreensão cardíaca, anestesia geral, déficits da memória devido à exposição a agentes anestésicos(...) |
| US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| US8697722B2 (en) * | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
| JO3250B1 (ar) * | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| RU2560729C2 (ru) * | 2010-01-11 | 2015-08-20 | АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи | Модуляторы никотиновых ацетилхолиновых рецепторов |
| PT3029039T (pt) | 2010-05-17 | 2017-11-28 | Forum Pharmaceuticals Inc | Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado |
| CA2830458A1 (en) * | 2011-03-18 | 2012-09-27 | Novartis Ag | Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease |
| EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
| US9246108B2 (en) | 2012-12-28 | 2016-01-26 | Dow Global Technologies Llc | Quinoline-benzoxazole derived compounds for electronic films and devices |
| WO2016100184A1 (en) | 2014-12-16 | 2016-06-23 | Forum Pharmaceuticals, Inc. | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| WO2016201096A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
| WO2017027600A1 (en) * | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| KR102240122B1 (ko) | 2020-09-09 | 2021-04-14 | 주식회사 비에스이엔지 | 멀칭재 펀칭 시스템 |
| CN117510404A (zh) * | 2023-11-29 | 2024-02-06 | 山西永津集团有限公司 | 一种4-氨基烟酸的制备方法 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4612319A (en) | 1982-04-14 | 1986-09-16 | Beecham Group P.L.C. | Bridged quinolizidinylbenzamides, compositions containing them and methods for their use |
| FR2531083B1 (fr) | 1982-06-29 | 1986-11-28 | Sandoz Sa | Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments |
| DE3429830A1 (de) | 1983-08-26 | 1985-03-07 | Sandoz-Patent-GmbH, 7850 Lörrach | Automatische carbonsaeure- und sulfonsaeureester oder -amide |
| US4888353A (en) | 1986-02-28 | 1989-12-19 | Erbamont, Inc. | Carboxamides useful as antiemetic or antipsychotic agents |
| US5175173A (en) | 1983-12-22 | 1992-12-29 | Sun Jung Hui | Carboxamides useful as antiemetic or antipsychotic agents |
| FR2557110B1 (fr) | 1983-12-23 | 1989-11-24 | Sandoz Sa | Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments |
| US4605652A (en) * | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
| DE3689974T2 (de) | 1985-03-14 | 1994-11-03 | Beecham Group Plc | Arzneimittel zur Behandlung von Emesis. |
| US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| GB8520616D0 (en) | 1985-08-16 | 1985-09-25 | Beecham Group Plc | Compounds |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| DE3782107T2 (de) | 1986-07-25 | 1993-04-01 | Beecham Group Plc | Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung. |
| NL8701682A (nl) | 1986-07-30 | 1988-02-16 | Sandoz Ag | Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten. |
| DE3752062T2 (de) | 1986-12-17 | 1997-09-11 | Glaxo Group Ltd | Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln |
| DE3788057T2 (de) | 1986-12-17 | 1994-03-03 | Glaxo Group Ltd | Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen. |
| US5322951A (en) | 1987-01-05 | 1994-06-21 | Beecham Group, P.L.C. | Certain 1-(2,3-dihydro-indole)carbonyl intermediates |
| GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| US4835162A (en) | 1987-02-12 | 1989-05-30 | Abood Leo G | Agonists and antagonists to nicotine as smoking deterents |
| DE3852145T2 (de) | 1987-02-18 | 1995-04-06 | Beecham Group Plc | Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten. |
| DE3881950T2 (de) | 1987-04-25 | 1993-09-30 | Beecham Group Plc | Azabicyclische Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen. |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US4921982A (en) | 1988-07-21 | 1990-05-01 | Eli Lilly And Company | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists |
| US4985420A (en) | 1987-12-10 | 1991-01-15 | Duphar International Research B.V. | 1,7-annelated indolecarboxylic acid esters and -amides |
| IE63474B1 (en) | 1987-12-24 | 1995-04-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US4863919A (en) | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
| US4924010A (en) | 1988-02-04 | 1990-05-08 | Rorer Pharmaceutical Corporation | Benzoxepins as intermediates to 5HT3 antagonists |
| DE3810552A1 (de) | 1988-03-29 | 1989-10-19 | Sandoz Ag | Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben |
| US4920219A (en) | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents |
| US4920227A (en) * | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Benzobicyclic carboxamide 5-HT3 antagonists |
| US4933445A (en) | 1988-11-29 | 1990-06-12 | Rorer Pharmaceutical Corporation | Heteroazabenzobicyclic carboxamide 5-HT3 antagonists |
| WO1990014347A1 (fr) | 1989-05-24 | 1990-11-29 | Nippon Shinyaku Co., Ltd. | Derives d'indole et medicament |
| EP0402056A3 (en) | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| CA2017621A1 (en) | 1989-06-23 | 1990-12-23 | Masayuki Kato | Indole derivatives and processes for preparation thereof |
| US4935511A (en) | 1989-09-26 | 1990-06-19 | Rorer Pharmaceutical Corporation | Benzoxazine and benzoxazepine carboxamide 5-HT3 antagonists |
| GB2236751B (en) | 1989-10-14 | 1993-04-28 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| GB8928837D0 (en) | 1989-12-21 | 1990-02-28 | Beecham Group Plc | Pharmaceuticals |
| EP0436245A1 (en) | 1989-12-27 | 1991-07-10 | Duphar International Research B.V | Substituted 3,4-annelated benzimidazol-2(1H)-ones |
| GB9009542D0 (en) | 1990-04-27 | 1990-06-20 | Beecham Group Plc | Novel compounds |
| AU7618991A (en) | 1990-05-14 | 1991-11-14 | Syntex (U.S.A.) Inc. | Novel tricyclic compounds |
| CA2090037A1 (en) | 1990-08-31 | 1992-03-01 | Shoichi Chokai | Indole derivatives and drugs |
| US5200415A (en) | 1990-11-01 | 1993-04-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives and their pharmaceutical use |
| US5189041A (en) | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| GB9027098D0 (en) | 1990-12-13 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
| HU211081B (en) | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| MX9102686A (es) | 1990-12-27 | 1994-01-31 | Erba Carlo Spa | Carboxamidas de dihidrobenzofurano y proceso para su preparacion. |
| GB9028105D0 (en) | 1990-12-27 | 1991-02-13 | Erba Carlo Spa | Process for the preparation of substituted benzofuran derivatives |
| US5114947A (en) | 1990-12-27 | 1992-05-19 | Erbamont Inc. | Method for alleviating anxiety using benzobicyclic carboxamides |
| US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
| DE4115215A1 (de) | 1991-05-10 | 1992-11-12 | Merck Patent Gmbh | Indolderivate |
| JPH05310732A (ja) | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| JP2699794B2 (ja) | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| US5273972A (en) | 1992-03-26 | 1993-12-28 | A. H. Robins Company, Incorporated | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates |
| SE9201478D0 (sv) | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5464161A (en) * | 1994-09-30 | 1995-11-07 | The United States Of America As Represented By The Secretary Of The Navy | Solid waste pulper |
| US5510478A (en) | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| GB9507882D0 (en) | 1995-04-18 | 1995-05-31 | Pharmacia Spa | Substituted dihydrobenzofuran derivatives as 5-ht4 agonists |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| ES2109190B1 (es) | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
| PT1147112E (pt) * | 1999-01-29 | 2004-03-31 | Abbott Lab | Derivados diazabiciclicos como liganos nicotinicos do receptor de acetilcolina |
| WO2000073431A2 (en) | 1999-05-27 | 2000-12-07 | Pharmacia & Upjohn Company | Methods and compositions for measuring ion channel conductance |
| JP2003513054A (ja) * | 1999-11-01 | 2003-04-08 | ターガセプト，インコーポレイテッド | アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用 |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| US6849620B2 (en) * | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
-
2002
- 2002-05-30 AR ARP020102021A patent/AR036041A1/es unknown
- 2002-06-04 PE PE2002000469A patent/PE20030040A1/es not_active Application Discontinuation
- 2002-06-06 AU AU2002348503A patent/AU2002348503A1/en not_active Abandoned
- 2002-06-06 EP EP02778934A patent/EP1404674A2/en not_active Withdrawn
- 2002-06-06 JP JP2003503625A patent/JP2004534065A/ja not_active Withdrawn
- 2002-06-06 WO PCT/US2002/016570 patent/WO2002100858A2/en not_active Ceased
- 2002-06-06 CA CA002445471A patent/CA2445471A1/en not_active Abandoned
- 2002-06-06 US US10/163,565 patent/US6828330B2/en not_active Expired - Fee Related
-
2004
- 2004-06-10 US US10/865,149 patent/US20040224977A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534065A5 (OSRAM) | ||
| JP7398391B2 (ja) | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 | |
| JP7034929B2 (ja) | 二環式アリールモノバクタム化合物及び細菌感染症を治療するためにそれらを使用する方法 | |
| AU687196B2 (en) | Pyrazolo and pyrrolopyridines | |
| CN1325501C (zh) | 杂环化合物 | |
| JP2023530319A (ja) | Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド | |
| JP2023530320A (ja) | Ｎａｖ１．８阻害剤としての５－オキソピロリジン－３－カルボキサミド | |
| US11142526B2 (en) | Spirocycle compounds and methods of making and using same | |
| JP2004534065A (ja) | 疾患治療用のキヌクリジン置換二環系へテロ芳香族化合物 | |
| JP2005508932A5 (OSRAM) | ||
| JP2005519922A5 (OSRAM) | ||
| CA2491506A1 (en) | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | |
| JP2005538125A5 (OSRAM) | ||
| JP2005527472A (ja) | 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン | |
| JP2005533868A5 (OSRAM) | ||
| JP2004517070A5 (OSRAM) | ||
| JP2014511898A5 (OSRAM) | ||
| KR102135230B1 (ko) | 세펨 화합물, 그의 제조 및 용도 | |
| JP4903936B2 (ja) | カンプトテシン類似体及びその調製方法 | |
| TW202214225A (zh) | Rip1k抑制劑 | |
| JP2005508969A5 (OSRAM) | ||
| JP2004525972A5 (OSRAM) | ||
| BR112021014402A2 (pt) | Métodos de tratamento de doença com inibidores de magl | |
| AU2017204748B2 (en) | (--)-Huperzine A processes and related compositions and methods of treatment | |
| KR20180101568A (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 |